A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 15 Feb 2017 Planned primary completion date changed from 1 Jun 2020 to 1 Mar 2020.
- 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.